Literature DB >> 34199044

Cardiac Amyloidosis with Discordant QRS Voltage between Frontal and Precordial Leads.

Csilla-Andrea Eötvös1,2, Roxana-Daiana Lazar2,3, Iulia-Georgiana Zehan2,3, Erna-Brigitta Lévay-Hail2,3, Giorgia Pastiu2,3, Mihaela Pop4, Anca Simona Bojan2,5, Sorin Pop2,3, Dan Blendea2,3.   

Abstract

Among the different types, immunoglobulin light chain (AL) cardiac amyloidosis is associated with the highest morbidity and mortality. The outcome, however, is significantly better when an early diagnosis is made and treatment initiated promptly. We present a case of cardiac amyloidosis with left ventricular hypertrophy criteria on the electrocardiogram. After 9 months of follow-up, the patient developed low voltage in the limb leads, while still maintaining the Cornell criteria for left ventricular hypertrophy as well. The relative apical sparing by the disease process, as well as decreased cancellation of the opposing left ventricular walls could be responsible for this phenomenon. The discordance between the voltage in the frontal leads and precordial leads, when present in conjunction with other findings, may be helpful in raising the clinical suspicion of cardiac amyloidosis.

Entities:  

Keywords:  amyloidosis; cardiomyopathy; low voltage

Mesh:

Year:  2021        PMID: 34199044     DOI: 10.3390/medicina57070660

Source DB:  PubMed          Journal:  Medicina (Kaunas)        ISSN: 1010-660X            Impact factor:   2.430


  22 in total

Review 1.  AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy.

Authors:  Rodney H Falk; Kevin M Alexander; Ronglih Liao; Sharmila Dorbala
Journal:  J Am Coll Cardiol       Date:  2016-09-20       Impact factor: 24.094

Review 2.  Unfolding Cardiac Amyloidosis -From Pathophysiology to Cure.

Authors:  Klemens Ablasser; Nicolas Verheyen; Theresa Glantschnig; Giulio Agnetti; Peter P Rainer
Journal:  Curr Med Chem       Date:  2019       Impact factor: 4.530

3.  Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role.

Authors:  Simone Longhi; Candida Cristina Quarta; Agnese Milandri; Massimiliano Lorenzini; Christian Gagliardi; Lisa Manuzzi; Maria Letizia Bacchi-Reggiani; Ornella Leone; Alessandra Ferlini; Antonio Russo; Ilaria Gallelli; Claudio Rapezzi
Journal:  Amyloid       Date:  2015-06-05       Impact factor: 7.141

4.  Baseline ECG Features and Arrhythmic Profile in Transthyretin Versus Light Chain Cardiac Amyloidosis.

Authors:  Francesco Cappelli; Elisa Vignini; Raffaele Martone; Stefano Perlini; Roberta Mussinelli; Anna Sabena; Sofia Morini; Martina Gabriele; Giulia Taborchi; Simone Bartolini; Angelica Lossi; Giulia Nardi; Niccolò Marchionni; Carlo Di Mario; Iacopo Olivotto; Federico Perfetto
Journal:  Circ Heart Fail       Date:  2020-03-13       Impact factor: 8.790

Review 5.  Amyloid cardiomyopathy.

Authors:  Arnt V Kristen
Journal:  Herz       Date:  2020-05       Impact factor: 1.443

Review 6.  How to Image Cardiac Amyloidosis: A Practical Approach.

Authors:  Sharmila Dorbala; Sarah Cuddy; Rodney H Falk
Journal:  JACC Cardiovasc Imaging       Date:  2019-10-11

7.  [Edoxaban in patients with atrial fibrillation and cancer].

Authors:  Nicola Maurea; Letizia Riva
Journal:  G Ital Cardiol (Rome)       Date:  2018-09

8.  The findings of electrocardiography in patients with cardiac amyloidosis.

Authors:  Zhongwei Cheng; Kongbo Zhu; Zhuang Tian; Dachun Zhao; Quancai Cui; Quan Fang
Journal:  Ann Noninvasive Electrocardiol       Date:  2012-11-22       Impact factor: 1.468

9.  Improvement of global longitudinal strain following high-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with amyloid light-chain cardiac amyloidosis: a case report.

Authors:  Yukina Hirata; Kenya Kusunose; Hirokazu Miki; Hirotsugu Yamada
Journal:  Eur Heart J Case Rep       Date:  2019-12-16

Review 10.  Cardiac amyloidosis-A review of current literature for the practicing physician.

Authors:  Samantha Ash; Eran Shorer; Devyani Ramgobin; Maique Vo; Jonathan Gibbons; Reshma Golamari; Rahul Jain; Rohit Jain
Journal:  Clin Cardiol       Date:  2021-02-17       Impact factor: 3.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.